Analysis of patient samples suggested a role for ICOS in the activity of anti-CTLA-4 therapy, including in melanoma patients treated with ipilumumab, where a sustained increase in the frequency of ICOS hi CD4+ T cells correlated with clinical benefit and improved survival [5]. The gene discussed is CTLA4; the disease is melanoma.